
Sign up to save your podcasts
Or


All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.
By Lemonada Media4.6
34723,472 ratings
All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.

37,050 Listeners

3,529 Listeners

87,249 Listeners

32,328 Listeners

9,468 Listeners

2,856 Listeners

12,531 Listeners

8,530 Listeners

320 Listeners

5,126 Listeners

758 Listeners

599 Listeners

16,010 Listeners

10,520 Listeners

853 Listeners

3,475 Listeners

387 Listeners

243 Listeners

10,619 Listeners

88 Listeners

120 Listeners

1,893 Listeners

449 Listeners

7,097 Listeners

1,186 Listeners

6,312 Listeners

617 Listeners

87 Listeners

469 Listeners

46 Listeners

151 Listeners

77 Listeners

22 Listeners

4,393 Listeners